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Background: Umbelliprenin is a natural compound, belonging to the class of sesquiterpene coumarins. Recently,
umbelliprenin has attracted the researchers' attention for its antitumor activities against skin tumors. Its effect on
lung cancer is largely unknown. The aim of our study was to investigate the effects of this natural compound,
which is expected to have low adverse effects, on lung cancer.
Methods: The QU-DB large cell and A549 adenocarcinoma lung cancer cell lines were treated with umbelliprenin.
IC50 values were estimated using methyl thiazolely diphenyl-tetrazolium bromide (MTT) assay, in which a decrease
in MTT reduction can occur as a result of cell death or cell proliferation inhibition. To quantify the rate of cell death
at IC50 values, flow cytometry using Annexin V-FITC (for apoptotic cells), and propidium iodide (for necrotic cells)
dyes were employed.
Results: Data from three independent MTT experiments in triplicate revealed that IC50 values for QU-DB and A549
were 47 ± 5.3 μM and 52 ± 1.97 μM, respectively. Annexin V/PI staining demonstrated that umbelliprenin treatment
at IC50 induced 50% cell death in QU-DB cells, but produced no significant death in A549 cells until increasing the
umbelliprenin concentration to IC80. The pattern of cell death was predominantly apoptosis in both cell lines. When
peripheral blood mononuclear cells were treated with 50 μM and less concentrations of umbelliprenin, no
suppressive effect was observed.
Conclusions: We found cytotoxic/anti-proliferative effects of umbelliprenin against two different types of lung
cancer cell lines.
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Lung cancer is one of the most common causes of can-
cer related deaths in most countries [1]. In Iran, lung
cancer is the third most frequent cancer in both men
and women [2]. The current 5 year survival of lung
cancer is about 10–15% mostly being attributed to late
diagnosis and inefficient therapy [3,4]. The limited
success and significant side effects of lung cancer treat-
ment with classic chemotherapeutic agents has led
researchers to find more efficient drugs with fewer side
effects [5,6].* Correspondence: mojtahediz@sums.ac.ir
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distribution, and reproduction in any mediumUmbelliprenin is synthesized by various Ferula plant
species such as Citrus Limon [7]. It is a prenylated
compound that belongs to the class of sesquiterpene
coumarins, and possesses a similar structure to aurap-
tene, a compound whose antitumor activities have
largely been investigated [8]. Recently, umbelliprenin has
attracted the researchers' attention for its antitumor
activities. It has been shown that the cell susceptibility
to umbelliprenin decreased in the order M4Beu (meta-
static pigmented malignant melanoma) > A549 (non-
small cell lung carcinoma) ≈ PC3 (androgen resistant
prostate carcinoma) > PA1 (ovary teratocarcinoma) >
human primary fibroblasts [9]. The anti-tumor effect of
umbelliprenin has also been demonstrated in vivo in a
mouse skin tumor model in which oral administration ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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illoma [10]. Umbelliprenin also showed an inhibitory
effect on the matrix metalloproteinases activity [11].
Matrix metalloproteinases are critical enzymes in cancer
metastatic cascade, such as migration, angiogenesis, and
invasiveness [12,13]. Despite inhibitory effects of umbel-
liprenin on tumor cells, treatment of peripheral blood
mononuclear cells (PBMNCs) with this compound pro-
tected them against DNA and chromosome damage
induced by H2O2 [12-14]
.
Methyl thiazolely diphenyl-tetrazolium bromide (MTT)
assay is frequently employed to determine the in vitro
index of cytotoxicity (IC). In metabolically active cells, the
reduction of water soluble MTT into an insoluble purple
formazan results in accumulation of purple formazan
crystals in cells. After solubilization of these crystals, the
comparison of the optical density (OD) between treated
and untreated cells gives a relative estimation of IC at dif-
ferent doses [15]. For determination of whether decreased
MTT reduction is either due to the cell death or decrease
in cell proliferation, other complementary tests such as
staining with fluorescent dyes annexin V-FITC for apop-
totic cells and propidium iodide (PI) for necrotic cells are
frequently performed. The sum of apoptotic and necrotic
cells represents the total rate of cell death [16].
The effect of umbelliprenin on lung cancer is poorly
understood. Here, we employed MTT assay and annexin
V/PI staining to investigate the effects of umbelliprenin
on lung cancer cells. The A549, a human pulmonary
adenocarcinoma cell line, and QU-DB, a human large
cell carcinoma line, as well as PBMNCs were treated
with umbelliprenin. IC50 was defined as the umbellipre-
nin concentration that resulted in a 50% decrease in the
OD of the test compound compared to that of untreated
cells. Then, annexin V/PI staining determined whether
(i) the decrease in MTT reduction is due to the cell
death or suppression of cell proliferation, and (ii) apop-
tosis or necrosis is the main cause of cell death.
Materials and methods
Cell culture
The study was approved by the Ethic Committee of
Shiraz University of Medical Sciences. Two human lung
cancer cell lines including A549 (adenocarcinoma) and
QU-DB (large cell) were obtained from the National Cell
Bank of Iran (NCBI), Pasteur Institute of Iran, Tehran,
Iran. PBMCs were obtained from healthy volunteers by
Ficoll-Hypaque density sedimentation. All the cells
were cultured in RPMI-1640 medium supplemented with
10% heat inactivated fetal bovine serum (FBS) (Gibco/
BRL, Germany), penicillin 100 U/ml. and streptomycin
100 μg/ml (Biosera, UK). They were maintained at 37°C
in a 5% CO2 incubator and the media were changed
every two day.Isolation of human peripheral blood mononuclear cells
Participants were informed that blood samples will be
used for a research project as healthy individuals, and
their written consent was obtained. Fifteen ml heparinized
blood samples were collected from healthy volunteers
(n=3, aged 30–35). Whole blood samples were diluted 1:1
with PBS, layered onto Ficoll-Paque (1.077 g/ml) at a vol-
ume ratio of 2:1 and centrifuged at 400 g for 30 min
at 20°C. The PBMCs layer was collected and washed
twice at 1500 rpm for 10 min with RPMI-1640 medium.
The supernatant was removed and the cells were resus-
pended in RPMI-1640 medium containing 10% FBS, 1%
penicillin and 100 μg/ml streptomycin. Cell viability
was tested (>98% viable cells) using the trypan-blue dye
exclusion method.
Umbelliprenin preparation
Umbelliprenin (C24H30O3, MW: 366) was synthesized
as previously described [17]. Umbelliprenin was first
dissolved in DMSO, and then this stock was dilluted in
CM10 media at 37ºC immediately before use to obtain a
maximum DMSO concentration of 0.5% (v/v).
MTT assay
Exponentially growing cells (T75 flasks) of A549 (5000
cells/well), and QU-DB (7000 cells/well) as well as
PBMNCs (1 x 105 cells/well) were cultured onto 96-well
plates in RPMI-1640 containing 10% FBS. Cells were
allowed to attach for 24 h before treatment. Then,
lung cancer cell lines were treated with fresh medium
containing umbelliprenin at different concentrations (10,
20, 50, 100, 200 μM). For PBMNCs, media containing
umbelliprenin were added at the time of cell seeding in
culture plates. ConA (2.5 μg/ml) treated PBMNCs were
used as a positive control for umbelliprenin. 0.5%
DMSO and untreated cells were used as the control of
solvent and negative control, respectively, in all experi-
ments. Wells containing medium with different concen-
trations of umbelliprenin without cells were used as the
control of compound. The plates were incubated for 24,
48 and 72 h. Then, 5 mg/ml MTT (sigma) was added
into each well, and the plates were incubated for 4 h
(37°C, 5% CO2). Media containing MTT were removed
and DMSO was added in each well to dissolve the
formazan crystals. Absorbance of the wells was read at
570 nm (A570) after 30 min of incubation at room
temperature (RT). At least three independent experi-
ments were done in triplicate for each experiment.
Annexin V/PI assay on lung cancer cell lines
To determine the extent of apoptosis and necrosis as
well as total cell death (apoptosis + necrosis) induced by
umbelliprenin on human lung cancer cell lines, annexin
V/PI staining (FITC Annexin V Apoptosis Detection Kit
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the exponential phase were treated with IC50 concentra-
tion of umbelliprenin for each cell lines. After 48 h, the
cells were trypsinized [18-20] (0.25% trypsin with a
longer incubation time was used for gentle dissociation
of the attached cells), and washed twice with PBS. The
pellets were resuspended in 1X binding buffer. After the
addition of annexin V-FITC, the cells were incubated
for 15 min at RT in the dark. PI dye was added at the
last 5 min of total incubation time. Flowcytometry was
done within one hour using FACSCalibur flow cytometer
(BD Biosciences, USA).
Statistical analysis
Dose–response curves and IC50 values were determined
using Curve Expert software, ver.1.3 and expressed as
mean ± standard deviation (SD) from at least three
independent experiments. Statistical tests including One-
way ANOVA, Tukey multiple comparison or unpaired
Student’s t tests were performed using GraphPad Prism,
ver.5 software. A p value of less than 0.05 was considered
as significant.
Results
MTT assay on lung cancer cell lines
Using MTT assay, we demonstrated that umbelliprenin
has antitumor activity on both A549 and QU-DB cell
lines, and that activity was dose and time-dependent.
The umbelliprenin concentration resulting in 50% of cell
cytotoxicity/proliferation inhibition was considered as
IC50. These values for A549 and QU-DB were found to
be 52 ± 1.97 and 47 ± 5.3 μM, respectively. The data
represent the mean ± SD of at least three independent
experiments done in triplicate. One way ANOVA ana-
lysis revealed a significant difference between umbelli-
prenin treated cells and 0.5% DMSO treated cells in all
experiments (p< 0.05). Figure 1 displays the summary of
these experiments on both A549 and QU-DB cells.
MTT assay on PBMNCs
PBMNCs were used to determine the effects of umbelli-
prenin on a normal, immune cell. In contrast to sup-
pressory effects of umbelliprenin at 10, 20, and 50 μM
on lung cancer cell lines, these concentrations caused no
inhibition on PBMNCs with even a higher proliferative
index compared to DMSO treated cell. However, at
higher doses (100 and 200 μM), umbelliprenin showed
some inhibitory activity on PBMNCs. Figure 2 indicates
the summary of these experiments on PBMNCs.
Annexin V/PI cell death (apoptosis + necrosis) and trypan
blue staining on lung cancer cell lines
For flow cytometry assays, cells were initially studied at
their IC50 values estimated using MTT. Annexin V/PIstaining at IC50 of umbelliprenin as compared to DMSO
treated controls after 48 h did not show any statistically
significant apoptosis or necrosis for A549 cell line. A
statistically significant cell death compared to controls
was observed after increasing umbelliprenin concentra-
tion to IC80 (88 μM). The predominant cell death was
apoptosis. QU-DB cells were more susceptible to death
induced by umbelliprenin than A549 cells, as they
showed 50% cell death after 48 h treatment at IC50
(50 μM). The dominant cell death was also apoptosis.
Figure 3 shows the result of annexin V/PI experiments
on both A549 and QU-DB cell lines. Annexin V positive
cells detected on FL1, indicated the apoptotic cells. PI
positive cells were detected on FL2 and showed death by
the necrosis. As it is indicated in Figure 3, the total
death rate, either apoptosis or necrosis, at IC50 after
48 h for QU-DB was 46.98% ± 8.7% (An+ = 41.7%, An
+/PI+ = 4.5%, and PI+ = 0.7%), and for A549 at IC80 after
48 h was 17.22% ± 6.29 (An+ = 15.9%, An+/PI+ = 0.39%,
and PI+ = 1.74%). These values are the subtraction of
the death rate in the control group from treated group
in each quadrant. The percentages of PI positive cells
were less than 5% for both cell lines, and the dominant
cell death type was apoptosis.
Our flowcytometry results were in accordance with
trypan blue viability test. At IC50 value, approximately
half of QU-DB cells were dead, however, even at IC80,
more than 50% of A549 cells were still viable in com-
parison to controls.
Discussion
Lung cancers are divided into small cell lung carcinoma
and non-small cell lung cancer (NSCLC). The majority
of lung cancer cases (about 80%) are NSCLC [1]. There
are three major subtypes for NSCLC: adenocarcinoma,
squamous cell and large call carcinoma (LCC). The lat-
ter has the poorest prognosis of NSCLC, followed by
adenocarcinoma [21].
Umbelliprenin has been recently recognized as a com-
pound with antitumor activities [9,10]. The data regard-
ing its effects on lung cancer are limited to a few studies
[9]. Here we evaluated the effects of this compound on
lung cancer cell lines QU-DB and A549 as well as
PBMNCs from healthy individuals using MTT assay.
Treatment of A549 and QU-DB cells with umbelliprenin
at different doses and intervals showed that umbellipre-
nin significantly suppressed lung cancer cell lines, and
this suppression was in a time-dose dependent manner.
These lung cancer cell lines showed approximately simi-
lar IC50 values (≈50μM) using MTT assay. However, we
observed the proliferative effects of umbelliprenin on
PBMNCs at 10, 20, and 50 μM doses.
To realize whether the decreased MTT reduction of
cancer cell lines caused by umbelliprenin is due to cell
Figure 1 (A) A549 cells and (B) QU-DB cells after 24, 48, and 72 h incubation with umbelliprenin. One way ANOVA and Tukey's Multiple
Comparison Tests revealed a significant difference between umbelliprenin treated and 0.5% DMSO treated cells. (*) Represents statistical
significance (p< 0.05).
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using annexin V/PI staining that simultaneously quanti-
fies apoptosis (Annexin V+) and necrosis (PI+). Apop-
tosis was added up to necrosis to quantify the total
death rate. In this study, the percentage of necrosis was
less than 5% in all experiments. Consistent with our
MTT assay, QU-DB cells showed approximately 50% cell
death at IC50 concentration after 48 h of umbelliprenin
treatment compared to DMSO control cells (p=0.002).
The total death rate induced by umbelliprenin was
46.98% ± 8.7%, of which 41.7% (An+), 4.5% (An+/PI+),
and 0.7% (PI+) were related to early apoptosis, late apop-
tosis and necrosis, respectively. The pattern of cell death
was in favor of apoptosis than necrosis. For A549 cell
line, we did not observe a significant difference in death
rate between treated and untreated cells until we
increased the concentration of umbelliprenin to IC80Figure 2 PBMNCs after 24, 48, and 72 h incubation with
different concentrations of umbelliprenin. At 10, 20, and 50 μM,
umbelliprenin showed no cytotoxicity or a mild proliferation
effects on PBMNCs, but at higher doses it showed cytotoxic/
anti-proliferative effects. 0.5% DMSO was used as the solvent control
and Con A 2.5 μg/ml as a positive control for proliferation.(p=0.022). The dominant cell death pattern in this ex-
periment was also apoptosis. The total death rate
induced by umbelliprenin was 17.22 ± 6.29, of which
early apoptosis, late apoptosis and necrosis patterns con-
stituted 15.9%, 0.39%, and 1.74% death cell types,
respectively. These flowcytometry results were partly in
agreement with trypan blue viability test in which the
number of dead cells was higher in QU-DB than A549
at IC50 value calculated using MTT colorimetric assay.
Our results indicate that umbelliprenin probably sup-
presses these cell lines with different pathways. Umbelli-
prenin is more cytotoxic against QU-DB, a large cell
lung cancer cell line compared to A549 adenocarcinoma
cell line.
Anti-cancer compounds have been divided into two
broad categories according to their ability to damage
DNA (cytotoxic), and/or inhibiting either nucleotide bio-
synthesis or mitosis (anti-proliferative) [22]. Umbellipre-
nin is structurally related to coumarin family [8].
Coumarin family has been shown both anti-proliferative
and cytotoxic effects in different cell lines and situations.
Coumarins can exert anti-proliferative effects through
inhibition of tubulin polymerization, and induction of
cell cycle arrest at G2/M transition of mitotic cell cycle
[23]. Coumarins can also induce apoptosis and cell death
by mitochondrial dependent and independent mechan-
isms. They may increase the reactive oxygen species
level and release of cytochrome c to the cytosol. Several
transcription factors, pro-apoptotic and apoptotic mole-
cules are involved in these pathways. For example, it has
been shown that apoptotic effects of a coumarin on
A549 cells is mediated through pro-apoptotic function
of NF-kB by induction of Bax and p53 expression, and
reduction of several signaling molecules such as Erk1/
Erk2, p38 and JNK [24].
Data regarding the molecular mechanisms of umbelli-
prenin, itself, are limited. The presence of the aliphatic
Figure 3 Annexin V/PI staining. (A) A549 cell treated by umbelliprenin or DMSO after 48 h. The apoptosis rate was significantly different
between umbelliprenin treated A549 cells compared to DMSO treated cells at IC80 of umbelliprenin (p=0.022). (B) QU-DB cell was treated by
umbelliprenin or DMSO after 48 h. Umbelliprenin induced apoptosis in QU-DB cells at IC50 (50 μM) value after 48 h (p=0.002). Numbers
adjacent to outlined squares indicate the percentage of cells in each quadrant. LL: Viable cells (Annexin V −/ PI −), LR: early apoptotic cells
(Annexin V +/ PI −), UL: late necrotic cells (Annexin V −/ PI +) and UR: late apoptotic/necrotic cells (Annexin V +/ PI +).
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umbelliprenin cytotoxic effects, but the main mechanism
in this regard is unknown [9]. Along with umbellipre-
nins’ cytotoxicity effects on various cancer cell lines, its
anti-proliferative effects on M4Beu cells via cell cycle
arrest in G1 phase has been shown before [9]. Other
cancer chemopreventive activity of umbelliprenin can
be related to its anti-oxidant activity [14] and its anti-
inflammatory effects. Umbelliprenin can inhibit the
function of 5-lipoxygenase and reduce the production of
lipoxygenase carcinogenic products [25]. All of known
functions of this compound can lead us to further
understanding of its anti-cancer effects.
The apoptotic and anti-proliferative effects of umbelli-
prenin on two lung cancer cell lines were demonstrated
in the present study using MTT and annexin V/PI
assays; some limitations still exist. Pairing of MTT and
annexin V/PI methods with other tests such as cell cycle
analysis by DNA content using PI staining and RNase A[9], or laser scanning confocal microscopy which moni-
tors several mitochondrial events during apoptosis such
as permeability transition and Ca2+ fluxes might be
further informative regarding anti-proliferative or cyto-
toxic effects of umbelliprenin [26]. It will be also in-
teresting to uncover the signalling pathways which
promote umbelliprenin-induced apoptosis in lung cancer
in future studies.
Conclusions
Using MTT assay and annexin V/PI staining, we
demonstrated that umbelliprenin can induce apoptosis
in both QU-DB large cell lung cancer and A549 adeno-
carcinoma cell line but at different doses. The ability
of umbelliprenin to induce lymphocyte proliferation
along with the induction of apoptosis or inhibition of
proliferation in cancer cells makes this compound an
attractive compound with fewer side effects for future
anti-cancer studies.
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